Alkermes Plc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
Good day, everybody. My name is Jason Gerberry. I cover specialty pharma and biotech at Bank of America. I am pleased to be introducing our next company presenter, Alkermes, and CEO, Richard Pops. Alkermes is -- we all know Alkermes as a neuroscience-focused company although the company has some interesting developments in its pipeline in the oncology space. The company recently provided its first quarter update and some of the implications around the COVID-19 pandemic. So maybe Richard, I don't know -- to start, I don't know if you have any prepared remarks or if you want to provide any color just on sort of the 1Q update and how COVID-19 is impacting your business, and then we can jump into more specific questions from there.
Yes. I'll make a couple of remarks, Jason. First, I'll say good morning, and I hope you and the folks in your firm are well. It is a remarkable time. And we were just saying before we got on the call
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |